256 related articles for article (PubMed ID: 1196134)
1. Effects of 1alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 on calcium and phosphorus metabolism in hypoparathyroidism.
Neer RM; Holick MF; DeLuca HF; Potts JT
Metabolism; 1975 Dec; 24(12):1403-13. PubMed ID: 1196134
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in our understanding of the vitamin D endocrine system.
De Luca HF
J Lab Clin Med; 1976 Jan; 87(1):7-26. PubMed ID: 173767
[TBL] [Abstract][Full Text] [Related]
5. Effects of 1alpha,25-dihydroxyvitamin D3 and Solanum glaucophyllum on intestinal calcium and phosphate transport and on plasma Ca, Mg and P levels in the rat.
Walling MW; Kimberg DV
Endocrinology; 1975 Dec; 97(6):1567-76. PubMed ID: 1204578
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D: the discovery of its metabolites and their therapeutic applications.
Beale MG; Chan JC; Oldham SB; Deluca HF
Pediatrics; 1976 May; 57(5):729-41. PubMed ID: 181725
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D metabolites and bone mineralization in man.
Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
[TBL] [Abstract][Full Text] [Related]
8. Acute actions of 1,25-dihydroxy-vitamin D3 in normal man: effect on calcium and parathyroid status.
Llach F; Coburn JW; Brickman AS; Kurokawa K; Norman AW; Canterbury JM; Reiss E
J Clin Endocrinol Metab; 1977 Jun; 44(6):1054-60. PubMed ID: 194908
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of vitamin D: current status.
DeLuca HF
Am J Clin Nutr; 1976 Nov; 29(11):1258-70. PubMed ID: 187053
[TBL] [Abstract][Full Text] [Related]
10. Effect of hydrochlorothiazide on 1,25-dihydroxyvitamin D3-induced changes in calcium metabolism in experimental hypoparathyroidism in rats.
Rizzoli R; Hugi K; Fleisch H; Bonjour JP
Clin Sci (Lond); 1981 Jan; 60(1):101-7. PubMed ID: 6894567
[TBL] [Abstract][Full Text] [Related]
11. Comparison of acute effects of 1.25- and 24.25-dihydroxy-vitamin D3 in normal subjects.
Heynen G; Cornet F; Franchimont P; Gaspar S; Plomteux G; Cession-Fossion G; Russel RG; Kanis JA
Acta Endocrinol (Copenh); 1981 Dec; 98(4):619-24. PubMed ID: 6975547
[TBL] [Abstract][Full Text] [Related]
12. Effect of 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on intestine and bone in glucocorticoid-treated patients.
Lund B; Andersen RB; Friis T; Hjorth L; Jørgensen FS; Norman AW; Sørensen OH
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():177s-181s. PubMed ID: 606415
[TBL] [Abstract][Full Text] [Related]
13. The kidney as an endocrine organ involved in the function of vitamin D.
DeLuca HF
Am J Med; 1975 Jan; 58(1):39-47. PubMed ID: 163578
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D-resistant rickets. A prototype of nutritional management of a genetic disorder.
Deluca HF
Curr Concepts Nutr; 1979; 8():3-32. PubMed ID: 230941
[TBL] [Abstract][Full Text] [Related]
15. Effect of 25-hydroxy-vitamin D3 on intestinal absorption of calcium in normal man and patients with renal failure.
Colodro IH; Brickman AS; Coburn JW; Osborn TW; Norman AW
Metabolism; 1978 Jun; 27(6):745-53. PubMed ID: 651659
[TBL] [Abstract][Full Text] [Related]
16. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
17. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance.
Balsan S; Garabedian M; Sorgniard R; Holick MF; Deluca HF
Pediatr Res; 1975 Jul; 9(7):586-93. PubMed ID: 169507
[TBL] [Abstract][Full Text] [Related]
18. Relative effectiveness of vitamin D metabolites in increasing bone mineral solubility.
Somerman MJ; Neuman WF
Calcif Tissue Int; 1981; 33(2):159-65. PubMed ID: 6783272
[TBL] [Abstract][Full Text] [Related]
19. Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis.
Mortensen L; Hyldstrup L; Charles P
Eur J Endocrinol; 1997 Jan; 136(1):52-60. PubMed ID: 9037127
[TBL] [Abstract][Full Text] [Related]
20. 1alpha-hydroxycholecalciferol in the treatment of hypoparathyroidism.
Jorgensen H; Vogt JH
Acta Med Scand; 1977 Jan; 201(1-2):3-7. PubMed ID: 835368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
